None

Osimertinib (Osimertinib) is an oral targeted therapy drug, mainly used to treat EGFR (epidermal growth factor receptor) gene mutation-positive advanced non-small cell lung cancer (NSCLC).

OimertinibOimertinib/OimertinibOriginal research drug, which has been launched in the domestic market, has now been included in the national medical insurance system, making it convenient for patients to purchase it in China. Its selling price remains at about 3,000 to 4,000 yuan, but the specific price and medical insurance reimbursement ratio may vary by region. Patients are advised to consult their local hospital or pharmacy for detailed consultation. Compared with domestic ones, the prices of foreign generic drugs are more affordable to the people, especially the versions launched in Laos and Bangladesh. Most of their prices are only around a few hundred yuan, which is far lower than the domestic market price. It is worth mentioning that these generic drugs are highly consistent with the original drugs in terms of pharmaceutical ingredients.

Osimertinib/Osimertinib belongs to the third generation of EGFRtyrosine kinase inhibitors. Compared with other EGFR inhibitors, it has higher Selective, able to inhibit EGFR sensitive mutations (such as Del19 and L858R mutations) as well as EGFR T790M mutation has relatively little impact on normal cells.

Osimertinib/The therapeutic scope of Osimertinib is mainly targeted at EGFRgene mutation-positive advanced NSCLC patients, especially those who are resistant to other EGFR inhibitors. For those who have Del19, L858R or T790Metc.

The dosage of Osimertinib/Osimertinib is generally 80 mg (mg) orally once a day, and can be taken with food or on an empty stomach. Patients should strictly abide by the doctor's recommendations and instructions during medication, conduct regular follow-up visits, and report any symptoms of discomfort in a timely manner to ensure the safety and effectiveness of treatment.

In summary, Osimertinib/Osimertinib is a targeted therapy drug that targets EGFRAdvanced gene mutation-positive NSCLC patients have higher therapeutic effects and less toxic side effects, providing patients with an effective treatment option and improving the survival rate and quality of life of patients with advanced lung cancer.